Guardant Health (GH) said Thursday it signed an agreement with the Abu Dhabi Public Health Center to launch a blood-based colorectal cancer screening using the Shield test.

Hikma Pharmaceuticals, a regional partner for Guardant in the Middle East and North Africa, arranged the deal, which will be implemented by the M42 healthcare system, the company said.

The Shield test will be included in Abu Dhabi Public Health Center's IFHAS screening program and will be offered at facilities run by Ambulatory Healthcare Services and M42 across Abu Dhabi, Al Ain, and the Al Dhafra region, Guardant added.

Organizers expect the program to screen roughly 10,000 individuals during its first year, according to the oncology company.

Financial details were not disclosed.

Shares of the company were up about 3.7% in recent trading.

Price: 49.43, Change: +1.78, Percent Change: +3.74